BPaL L Regimen (Bedaquiline, Pretomanid Linezolid and Levofloxacin)

Dr Francesca Conradie

UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG 100 1922 2022

USAID FROM THE AMERICAN PEOPLE

health
Department:
Health
REPUBLIC OF SOUTH AFRICA

The NEW ENGLAND JOURNAL of MEDICINE

Treatment of Highly Drug-Resistant Pulmonary TB

NIX-TB, AN OPEN-LABEL, SINGLE-GROUP STUDY

109 Patients
with confirmed tuberculosis



Three-drug regimen (26 wk)

Bedaquiline

Pretomanid
(recently approved)

Linezolid

XDR tuberculosis
N=71
(65%)

Nonresponsive or treatment-intolerant MDR tuberculosis
N=38
(34%)

Clinical resolution at 6 mo after therapy

90% of all patients had favorable outcomes
95% CI, 83–95

89%
95% CI, 79–95

92%
95% CI, 79–98

Linezolid associated with peripheral neuropathy (81%) and myelosuppression (48%)

F. Conradie et al. 10.1056/NEJMoa1901814

Study Design



*Additional 3 months if sputum culture positive between week 16 and week 26 treatment visits

Pa pretomanid dose = 200 mg daily
B bedaquiline dose = 200 mg x 8 weeks, then 100 mg x 18 weeks

† Pre-2021 WHO Definitions of XDR-TB and Pre-XDR-TB

TB Practecal
Innovating MDR-TB Treatment

TRIAL DESIGN

- All 3 investigational arms met criteria for stage 2 eligibility.
- No major safety signals were detected.
- The BPaLM regimen was selected to continue to stage 2.



BPaL Clinical Access Program

UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG 1922 2022

USAID FROM THE AMERICAN PEOPLE

health
Department:
Health
REPUBLIC OF SOUTH AFRICA

South Africa burden of disease



Population 60,511,300
0.76% of the world's population
3% of the Worldwide TB burden

Inclusion criteria for the BPaL CAP

Age 14+

Pulmonary RR-TB diagnosis with quinolone resistance (PreXDR-TB) or quinolone sensitive and clinician recommendation for a shorter regimen Less than 56 days exposure to BDQ or LNZ

BDQ 400mg daily for two weeks than 200mg tiw for 6 months

Linezolid 600mg daily for 6 months

Pretomanid 200mg daily for 6 months

Demographics

	Median (IQR)	Min-Max
Age (years)	41 (35-50)	17-82
BMI (m/kg^2)	20.0 (17.5-22.9)	12.5-37
	N	%
Gender		
Female	84	37%
Male	140	63%
HIV Status		
HIV Positive	122	55%
Diabetes	18	8%

Interim outcomes Nov 2022

	Number of participants
Started on BPaL regimen	224
Completed at least 60 days of treatment and are not found to be resistant to bedaquiline	194
Culture positive at week 8 (N=194)	4%
Median (IQR) time in days to conversion (N=95)	57 days (30-85)
Conversion occurred within the first six months of treatment (N=95)	92 (96.8%)